These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1516 related articles for article (PubMed ID: 24335877)
21. Evaluation of tricine and EDDA as Co-ligands for 99mTc-labeled HYNIC-MSH analogs for melanoma imaging. Garcia MF; Zhang X; Gallazzi F; Fernandez M; Moreno M; Gambini JP; Porcal W; Cabral P; Quinn TP Anticancer Agents Med Chem; 2015; 15(1):122-30. PubMed ID: 25175799 [TBL] [Abstract][Full Text] [Related]
22. [Comparative study of the biodistribution of (99m)Tc-HYNIC-Lys3-Bombesin obtained with the EDDA/tricine and NA/tricine as coligands]. Hernández-Cairo A; Perera-Pintado A; Prats-Capote A; Batista-Cuellar JF; Casacó-Santana C Rev Esp Med Nucl Imagen Mol; 2012; 31(2):61-5. PubMed ID: 22305264 [TBL] [Abstract][Full Text] [Related]
23. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma. Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564 [TBL] [Abstract][Full Text] [Related]
24. A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas. Medina-García V; Ocampo-García BE; Ferro-Flores G; Santos-Cuevas CL; Aranda-Lara L; García-Becerra R; Ordaz-Rosado D; Melendez-Alafort L Nucl Med Biol; 2015 Dec; 42(12):911-6. PubMed ID: 26364504 [TBL] [Abstract][Full Text] [Related]
25. Kit formulated asialoglycoprotein receptor targeting tracer based on copolymer for liver SPECT imaging. Liu C; Guo Z; Zhang P; Song M; Zhao Z; Wu X; Zhang X Nucl Med Biol; 2014 Aug; 41(7):587-93. PubMed ID: 24815356 [TBL] [Abstract][Full Text] [Related]
26. In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands. Su ZF; He J; Rusckowski M; Hnatowich DJ Nucl Med Biol; 2003 Feb; 30(2):141-9. PubMed ID: 12623113 [TBL] [Abstract][Full Text] [Related]
27. Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides. Yang Y; Ji S; Liu S Bioconjug Chem; 2014 Sep; 25(9):1720-9. PubMed ID: 25144854 [TBL] [Abstract][Full Text] [Related]
28. 99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression. Jia B; Shi J; Yang Z; Xu B; Liu Z; Zhao H; Liu S; Wang F Bioconjug Chem; 2006; 17(4):1069-76. PubMed ID: 16848417 [TBL] [Abstract][Full Text] [Related]
31. Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Liu S; Hsieh WY; Kim YS; Mohammed SI Bioconjug Chem; 2005; 16(6):1580-8. PubMed ID: 16287258 [TBL] [Abstract][Full Text] [Related]
32. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis. Guggenberg EV; Mikolajczak R; Janota B; Riccabona G; Decristoforo C J Pharm Sci; 2004 Oct; 93(10):2497-506. PubMed ID: 15349959 [TBL] [Abstract][Full Text] [Related]
33. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743 [TBL] [Abstract][Full Text] [Related]
34. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384 [TBL] [Abstract][Full Text] [Related]
35. Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Faintuch BL; Teodoro R; Duatti A; Muramoto E; Faintuch S; Smith CJ Nucl Med Biol; 2008 May; 35(4):401-11. PubMed ID: 18482677 [TBL] [Abstract][Full Text] [Related]
36. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. von Guggenberg E; Dietrich H; Skvortsova I; Gabriel M; Virgolini IJ; Decristoforo C Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1209-18. PubMed ID: 17308920 [TBL] [Abstract][Full Text] [Related]
37. In vitro evaluation of (99m)Tc-EDDA/tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptor positive tumor cell lines. Yurt Lambrecht F; Durkan K; Ozgür A; Gündüz C; Avcı CB; Susluer SY J Drug Target; 2013 May; 21(4):383-8. PubMed ID: 23301856 [TBL] [Abstract][Full Text] [Related]
38. 99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand. Wang J; Kim YS; Liu S Bioconjug Chem; 2008 Mar; 19(3):634-42. PubMed ID: 18281926 [TBL] [Abstract][Full Text] [Related]
39. (99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors. Dong C; Zhao H; Yang S; Shi J; Huang J; Cui L; Zhong L; Jin X; Li F; Liu Z; Jia B; Wang F Mol Pharm; 2013 Aug; 10(8):2925-33. PubMed ID: 23768172 [TBL] [Abstract][Full Text] [Related]